Genelux (NASDAQ:GNLX – Get Free Report) issued its earnings results on Friday. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09), Zacks reports.
Genelux Trading Up 1.7 %
GNLX opened at $3.08 on Friday. The stock’s fifty day simple moving average is $4.06 and its 200 day simple moving average is $3.10. Genelux has a 1-year low of $1.60 and a 1-year high of $6.50. The stock has a market cap of $106.38 million, a PE ratio of -3.24 and a beta of -1.41.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Genelux in a research note on Tuesday. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $18.25.
Genelux Company Profile
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Featured Stories
- Five stocks we like better than Genelux
- Transportation Stocks Investing
- MarketBeat Week in Review – 03/24 – 03/28
- How to invest in marijuana stocks in 7 steps
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
